ClinVar Genomic variation as it relates to human health
NC_000006.12:g.31575254G>A
No data submitted for somatic clinical impact
No data submitted for oncogenicity
Variant Details
- Identifiers
-
NC_000006.12:g.31575254G>A
Variation ID: 225964 Accession: VCV000225964.9
- Type and length
-
single nucleotide variant, 1 bp
- Location
-
Cytogenetic: 6p21.33 6: 31575254 (GRCh38) [ NCBI UCSC ] 6: 31543031 (GRCh37) [ NCBI UCSC ]
- Timeline in ClinVar
-
First in ClinVar Help The date this variant first appeared in ClinVar with each type of classification.
Last submission Help The date of the most recent submission for each type of classification for this variant.
Last evaluated Help The most recent date that a submitter evaluated this variant for each type of classification.
Germline Sep 9, 2016 Feb 20, 2022 Mar 24, 2021 - HGVS
-
Nucleotide Protein Molecular
consequenceNC_000006.12:g.31575254G>A NC_000006.11:g.31543031G>A NG_007462.1:g.4682G>A NG_012010.1:g.8156G>A - Protein change
- -
- Other names
-
-308G-A
- Canonical SPDI
- NC_000006.12:31575253:G:A
-
Functional
consequence HelpThe effect of the variant on RNA or protein function, based on experimental evidence from submitters.
- -
-
Global minor allele
frequency (GMAF) HelpThe global minor allele frequency calculated by the 1000 Genomes Project. The minor allele at this location is indicated in parentheses and may be different from the allele represented by this VCV record.
-
0.09026 (A)
-
Allele frequency
Help
The frequency of the allele represented by this VCV record.
-
1000 Genomes Project 0.09026
1000 Genomes Project 30x 0.09307
The Genome Aggregation Database (gnomAD), exomes 0.11633
Trans-Omics for Precision Medicine (TOPMed) 0.13494
NHLBI Exome Sequencing Project (ESP) Exome Variant Server 0.14142
The Genome Aggregation Database (gnomAD) 0.14163
Exome Aggregation Consortium (ExAC) 0.16159
- Links
Genes
Gene | OMIM | ClinGen Gene Dosage Sensitivity Curation |
Variation Viewer
Help
Links to Variation Viewer, a genome browser to view variation data from NCBI databases. |
Related variants | ||
---|---|---|---|---|---|---|
HI score
Help
The haploinsufficiency score for the gene, curated by ClinGen’s Dosage Sensitivity Curation task team. |
TS score
Help
The triplosensitivity score for the gene, curated by ClinGen’s Dosage Sensitivity Curation task team. |
Within gene
Help
The number of variants in ClinVar that are contained within this gene, with a link to view the list of variants. |
All
Help
The number of variants in ClinVar for this gene, including smaller variants within the gene and larger CNVs that overlap or fully contain the gene. |
|||
TNF | - | - |
GRCh38 GRCh38 GRCh38 GRCh38 GRCh38 GRCh38 GRCh38 GRCh38 GRCh37 |
19 | 28 |
Conditions - Germline
Condition
Help
The condition for this variant-condition (RCV) record in ClinVar. |
Classification
Help
The aggregate germline classification for this variant-condition (RCV) record in ClinVar. The number of submissions that contribute to this aggregate classification is shown in parentheses. (# of submissions) |
Review status
Help
The aggregate review status for this variant-condition (RCV) record in ClinVar. This value is calculated by NCBI based on data from submitters. Read our rules for calculating the review status. |
Last evaluated
Help
The most recent date that a submitter evaluated this variant for the condition. |
Variation/condition record
Help
The RCV accession number, with most recent version number, for the variant-condition record, with a link to the RCV web page. |
---|---|---|---|---|
drug response (1) |
reviewed by expert panel
|
Mar 24, 2021 | RCV000211242.13 | |
Susceptibility to severe coronavirus disease (COVID-19)
|
Uncertain significance (1) |
no assertion criteria provided
|
Feb 9, 2021 | RCV001354056.9 |
risk factor (1) |
no assertion criteria provided
|
Mar 1, 2006 | RCV001807634.9 | |
risk factor (1) |
no assertion criteria provided
|
Mar 1, 2006 | RCV001807635.9 | |
risk factor (1) |
no assertion criteria provided
|
Mar 1, 2006 | RCV001807636.9 | |
not provided
|
risk factor (1) |
no assertion criteria provided
|
Mar 1, 2006 | RCV001807637.9 |
Affects (1) |
no assertion criteria provided
|
Oct 20, 2021 | RCV001824024.10 | |
not provided
|
risk factor (1) |
no assertion criteria provided
|
Mar 1, 2006 | RCV001807638.9 |
risk factor (1) |
no assertion criteria provided
|
Mar 1, 2006 | RCV001807640.9 | |
not provided
|
risk factor (1) |
no assertion criteria provided
|
Mar 1, 2006 | RCV001807639.9 |
Susceptibility to severe coronavirus disease (COVID-19) due to high plasma levels of TNF, TNFR, and/or TNFR4
|
Uncertain significance (1) |
no assertion criteria provided
|
Aug 7, 2021 | RCV001836755.9 |
click to load more click to collapse |
Submissions - Germline
Classification
Help
The submitted germline classification for each SCV record. (Last evaluated) |
Review status
Help
Stars represent the review status, or the level of review supporting the submitted (SCV) record. This value is calculated by NCBI based on data from the submitter. Read our rules for calculating the review status. This column also includes a link to the submitter’s assertion criteria if provided, and the collection method. (Assertion criteria) |
Condition
Help
The condition for the classification, provided by the submitter for this submitted (SCV) record. This column also includes the affected status and allele origin of individuals observed with this variant. |
Submitter
Help
The submitting organization for this submitted (SCV) record. This column also includes the SCV accession and version number, the date this SCV first appeared in ClinVar, and the date that this SCV was last updated in ClinVar. |
More information
Help
This column includes more information supporting the classification, including citations, the comment on classification, and detailed evidence provided as observations of the variant by the submitter. |
|
---|---|---|---|---|---|
drug response
Drug-variant association: Efficacy
(Mar 24, 2021)
|
reviewed by expert panel
Method: curation
|
etanercept response - Efficacy
Drug used for
Arthritis, Psoriatic
, Arthritis, Rheumatoid
, Crohn Disease
, Inflammation
, Psoriasis
, and Spondylitis, Ankylosing
Affected status: yes
Allele origin:
germline
|
PharmGKB
Accession: SCV000268228.4
First in ClinVar: May 22, 2016 Last updated: Dec 12, 2021
Comment:
Drug is not necessarily used to treat response condition
|
Comment:
PharmGKB Level of Evidence 2B: Variants in Level 2B clinical annotations are not in PharmGKB’s Tier 1 VIPs. These clinical annotations describe variant-drug combinations with … (more)
PharmGKB Level of Evidence 2B: Variants in Level 2B clinical annotations are not in PharmGKB’s Tier 1 VIPs. These clinical annotations describe variant-drug combinations with a moderate level of evidence supporting the association. For example, the association may be found in multiple cohorts, but there may be a minority of studies that do not support the majority assertion. Level 2B clinical annotations must be supported by at least two independent publications. (less)
|
|
risk factor
(Mar 01, 2006)
|
no assertion criteria provided
Method: literature only
|
MIGRAINE WITHOUT AURA, SUSCEPTIBILITY TO
Affected status: not provided
Allele origin:
germline
|
OMIM
Accession: SCV000033439.2
First in ClinVar: Apr 04, 2013 Last updated: Sep 09, 2016 |
Comment on evidence:
Mira et al. (1999) referred to the TNFA promoter polymorphisms at position -308 as TNF1 for guanine and TNF2 for adenine. In a multicenter study … (more)
Mira et al. (1999) referred to the TNFA promoter polymorphisms at position -308 as TNF1 for guanine and TNF2 for adenine. In a multicenter study involving 7 institutions, they found a significant association between the TNF2 allele and susceptibility to septic shock and death from septic shock. The septic shock group was defined by the following 6 criteria within a 12-hour period: (1) clinical evidence of infection; (2) hyperthermia or hypothermia; (3) tachycardia; (4) tachypnea; (5) necessity for vasopressor to maintain systolic blood pressure; and (6) evidence of inadequate organ function or perfusion. Moraes et al. (2001) found that the TNF2 polymorphism is significantly associated with a stronger response (Mitsuda reaction) to lepromin in borderline tuberculoid leprosy patients. Epigenetic factors such as a history of BCG vaccination or a reversal reaction, but not both, were also associated with boosted Mitsuda reactions. Moraes et al. (2001) concluded that augmented TNF production may be associated with the TNF2 allele and an increased granulomatous response. Ma et al. (1998) found a higher frequency of the rare T2 TNFA polymorphism (-308G-A) in 43 Japanese Guillain-Barre syndrome (139393) patients who had had antecedent infection with C. jejuni than in 85 community controls. Witte et al. (2002) evaluated the relation between the -308G-A promoter polymorphism and risk of asthma (600807) in 236 cases and 275 nonasthmatic controls. Logistic regression analyses indicated that having 1 or 2 copies of the -308A allele increased the risk of asthma (odds ratio = 1.58), the magnitude of which was increased when restricting the cases to those with acute asthma (odds ratio = 1.86, P = 0.04) or further restricting the subjects to those with a family history of asthma and those of European American ancestry (odds ratio = 3.16, P = 0.04). Shin et al. (2004) genotyped 550 Korean asthmatics and 171 Korean controls at 5 SNPs in TNFA and 2 SNPs in TNFB. Six common haplotypes could be constructed in the TNF gene cluster. The -308G-A polymorphism showed a significant association with the risk of asthma (p = 0.0004). The frequency of the -308A allele-containing genotype in asthmatics (9.8%) was much lower than that in normal controls (22.9%). The protective effects of this polymorphism on asthma were also evident in separated subgroups by atopic status (p = 0.05 in nonatopic subjects and p = 0.003 in atopic subjects). The most common haplotype of the TNF gene cluster (TNF-ht1-GGTCCGG) was associated with total serum IgE levels (147050) in asthma patients, especially in nonatopic patients (p = 0.004). Shin et al. (2004) concluded that genetic variants of TNF may be involved in the development of asthma and total serum IgE level in bronchial asthma patients. Aoki et al. (2006) did not find a significant association between the TNF -308G-A polymorphism and childhood atopic asthma in 2 independent Japanese populations; however, metaanalysis of a total of 2,477 asthma patients and 3,217 control individuals showed that the -308G-A polymorphism was significantly associated with asthma. The combined odds ratio was 1.46 for fixed or random effects (p = 0.0000001 and p = 0.00014, respectively). Quasney et al. (2001) stated that immunologic mechanisms resulting in macrophage infiltration and glial cell activation in the brain are thought to be involved in the pathophysiology of HIV dementia. Moreover, elevated levels of TNF-alpha have been found in the brains of patients with HIV dementia. In a study of 16 patients with HIV dementia, 45 HIV-infected patients without dementia, and 231 controls, they found an increased frequency of the -308A allele in patients with HIV dementia (0.28 vs 0.11 in controls and 0.07 in HIV patients without dementia). There were no individuals with the A/A genotype in either of the HIV-infected groups. Quasney et al. (2001) noted that the -308A allele is associated with higher TNF-alpha secretion in response to an inflammatory stimulus and that evidence has shown a role for TNF-alpha in neuronal damage, thus suggesting a genetic predisposition to the development of HIV dementia. Cox et al. (1994) reported that the -308A allele has an increased frequency in type I diabetes mellitus (222100). Krikovszky et al. (2002) studied ambulatory blood pressure in 126 Hungarian adolescents with type I diabetes mellitus. They found that the prevalence of the -308A allele was higher in diabetic adolescents than in the Hungarian reference population. TNFA genotype was associated with both systolic and diastolic blood pressure values. The -308A allele carrier state appeared to be associated with lower systolic and diastolic blood pressure values. Szalai et al. (2002) found an increased frequency of the C4B*Q0 allele (see 120820) in patients with severe coronary artery disease (CAD) who underwent bypass surgery compared to healthy controls (14.2% vs 9.9%). Investigation of specific allelic combinations revealed that C4B*Q0 in combination with the TNF-alpha -308A allele was significantly higher in CAD patients, particularly those with preoperative myocardial infarction. In a study of 147 patients with psoriatic arthritis (607507) and 389 controls, Balding et al. (2003) found that the -308A allele was significantly associated with both the presence and progression of joint erosions in psoriatic arthritis, and that the AA genotype was associated with the lowest mean age at onset of psoriasis (p = 0.0081). In a group of 261 patients with migraine without aura (see, e.g., 157300), Rainero et al. (2004) found that the G/G genotype was associated with an increased risk of migraine (odds ratio of 3.30). Rainero et al. (2004) suggested that TNF-alpha may be involved in the pathogenesis of migraine, perhaps due to its effect on cerebral blood flow; alternatively, a closely linked locus may be involved. In a metaanalysis of 19 studies, Lee et al. (2006) found an association between the -308A/A genotype and the -308A allele and systemic lupus erythematosus (SLE; 152700) in European-derived population (odds ratio of 4.0 for A/A and 2.1 for the A allele), but not in Asian-derived populations. (less)
|
|
risk factor
(Mar 01, 2006)
|
no assertion criteria provided
Method: literature only
|
PSORIATIC ARTHRITIS, SUSCEPTIBILITY TO
Affected status: not provided
Allele origin:
germline
|
OMIM
Accession: SCV000033440.2
First in ClinVar: Apr 04, 2013 Last updated: Sep 09, 2016 |
Comment on evidence:
Mira et al. (1999) referred to the TNFA promoter polymorphisms at position -308 as TNF1 for guanine and TNF2 for adenine. In a multicenter study … (more)
Mira et al. (1999) referred to the TNFA promoter polymorphisms at position -308 as TNF1 for guanine and TNF2 for adenine. In a multicenter study involving 7 institutions, they found a significant association between the TNF2 allele and susceptibility to septic shock and death from septic shock. The septic shock group was defined by the following 6 criteria within a 12-hour period: (1) clinical evidence of infection; (2) hyperthermia or hypothermia; (3) tachycardia; (4) tachypnea; (5) necessity for vasopressor to maintain systolic blood pressure; and (6) evidence of inadequate organ function or perfusion. Moraes et al. (2001) found that the TNF2 polymorphism is significantly associated with a stronger response (Mitsuda reaction) to lepromin in borderline tuberculoid leprosy patients. Epigenetic factors such as a history of BCG vaccination or a reversal reaction, but not both, were also associated with boosted Mitsuda reactions. Moraes et al. (2001) concluded that augmented TNF production may be associated with the TNF2 allele and an increased granulomatous response. Ma et al. (1998) found a higher frequency of the rare T2 TNFA polymorphism (-308G-A) in 43 Japanese Guillain-Barre syndrome (139393) patients who had had antecedent infection with C. jejuni than in 85 community controls. Witte et al. (2002) evaluated the relation between the -308G-A promoter polymorphism and risk of asthma (600807) in 236 cases and 275 nonasthmatic controls. Logistic regression analyses indicated that having 1 or 2 copies of the -308A allele increased the risk of asthma (odds ratio = 1.58), the magnitude of which was increased when restricting the cases to those with acute asthma (odds ratio = 1.86, P = 0.04) or further restricting the subjects to those with a family history of asthma and those of European American ancestry (odds ratio = 3.16, P = 0.04). Shin et al. (2004) genotyped 550 Korean asthmatics and 171 Korean controls at 5 SNPs in TNFA and 2 SNPs in TNFB. Six common haplotypes could be constructed in the TNF gene cluster. The -308G-A polymorphism showed a significant association with the risk of asthma (p = 0.0004). The frequency of the -308A allele-containing genotype in asthmatics (9.8%) was much lower than that in normal controls (22.9%). The protective effects of this polymorphism on asthma were also evident in separated subgroups by atopic status (p = 0.05 in nonatopic subjects and p = 0.003 in atopic subjects). The most common haplotype of the TNF gene cluster (TNF-ht1-GGTCCGG) was associated with total serum IgE levels (147050) in asthma patients, especially in nonatopic patients (p = 0.004). Shin et al. (2004) concluded that genetic variants of TNF may be involved in the development of asthma and total serum IgE level in bronchial asthma patients. Aoki et al. (2006) did not find a significant association between the TNF -308G-A polymorphism and childhood atopic asthma in 2 independent Japanese populations; however, metaanalysis of a total of 2,477 asthma patients and 3,217 control individuals showed that the -308G-A polymorphism was significantly associated with asthma. The combined odds ratio was 1.46 for fixed or random effects (p = 0.0000001 and p = 0.00014, respectively). Quasney et al. (2001) stated that immunologic mechanisms resulting in macrophage infiltration and glial cell activation in the brain are thought to be involved in the pathophysiology of HIV dementia. Moreover, elevated levels of TNF-alpha have been found in the brains of patients with HIV dementia. In a study of 16 patients with HIV dementia, 45 HIV-infected patients without dementia, and 231 controls, they found an increased frequency of the -308A allele in patients with HIV dementia (0.28 vs 0.11 in controls and 0.07 in HIV patients without dementia). There were no individuals with the A/A genotype in either of the HIV-infected groups. Quasney et al. (2001) noted that the -308A allele is associated with higher TNF-alpha secretion in response to an inflammatory stimulus and that evidence has shown a role for TNF-alpha in neuronal damage, thus suggesting a genetic predisposition to the development of HIV dementia. Cox et al. (1994) reported that the -308A allele has an increased frequency in type I diabetes mellitus (222100). Krikovszky et al. (2002) studied ambulatory blood pressure in 126 Hungarian adolescents with type I diabetes mellitus. They found that the prevalence of the -308A allele was higher in diabetic adolescents than in the Hungarian reference population. TNFA genotype was associated with both systolic and diastolic blood pressure values. The -308A allele carrier state appeared to be associated with lower systolic and diastolic blood pressure values. Szalai et al. (2002) found an increased frequency of the C4B*Q0 allele (see 120820) in patients with severe coronary artery disease (CAD) who underwent bypass surgery compared to healthy controls (14.2% vs 9.9%). Investigation of specific allelic combinations revealed that C4B*Q0 in combination with the TNF-alpha -308A allele was significantly higher in CAD patients, particularly those with preoperative myocardial infarction. In a study of 147 patients with psoriatic arthritis (607507) and 389 controls, Balding et al. (2003) found that the -308A allele was significantly associated with both the presence and progression of joint erosions in psoriatic arthritis, and that the AA genotype was associated with the lowest mean age at onset of psoriasis (p = 0.0081). In a group of 261 patients with migraine without aura (see, e.g., 157300), Rainero et al. (2004) found that the G/G genotype was associated with an increased risk of migraine (odds ratio of 3.30). Rainero et al. (2004) suggested that TNF-alpha may be involved in the pathogenesis of migraine, perhaps due to its effect on cerebral blood flow; alternatively, a closely linked locus may be involved. In a metaanalysis of 19 studies, Lee et al. (2006) found an association between the -308A/A genotype and the -308A allele and systemic lupus erythematosus (SLE; 152700) in European-derived population (odds ratio of 4.0 for A/A and 2.1 for the A allele), but not in Asian-derived populations. (less)
|
|
risk factor
(Mar 01, 2006)
|
no assertion criteria provided
Method: literature only
|
SYSTEMIC LUPUS ERYTHEMATOSUS, SUSCEPTIBILITY TO
Affected status: not provided
Allele origin:
germline
|
OMIM
Accession: SCV000033441.2
First in ClinVar: Apr 04, 2013 Last updated: Sep 09, 2016 |
Comment on evidence:
Mira et al. (1999) referred to the TNFA promoter polymorphisms at position -308 as TNF1 for guanine and TNF2 for adenine. In a multicenter study … (more)
Mira et al. (1999) referred to the TNFA promoter polymorphisms at position -308 as TNF1 for guanine and TNF2 for adenine. In a multicenter study involving 7 institutions, they found a significant association between the TNF2 allele and susceptibility to septic shock and death from septic shock. The septic shock group was defined by the following 6 criteria within a 12-hour period: (1) clinical evidence of infection; (2) hyperthermia or hypothermia; (3) tachycardia; (4) tachypnea; (5) necessity for vasopressor to maintain systolic blood pressure; and (6) evidence of inadequate organ function or perfusion. Moraes et al. (2001) found that the TNF2 polymorphism is significantly associated with a stronger response (Mitsuda reaction) to lepromin in borderline tuberculoid leprosy patients. Epigenetic factors such as a history of BCG vaccination or a reversal reaction, but not both, were also associated with boosted Mitsuda reactions. Moraes et al. (2001) concluded that augmented TNF production may be associated with the TNF2 allele and an increased granulomatous response. Ma et al. (1998) found a higher frequency of the rare T2 TNFA polymorphism (-308G-A) in 43 Japanese Guillain-Barre syndrome (139393) patients who had had antecedent infection with C. jejuni than in 85 community controls. Witte et al. (2002) evaluated the relation between the -308G-A promoter polymorphism and risk of asthma (600807) in 236 cases and 275 nonasthmatic controls. Logistic regression analyses indicated that having 1 or 2 copies of the -308A allele increased the risk of asthma (odds ratio = 1.58), the magnitude of which was increased when restricting the cases to those with acute asthma (odds ratio = 1.86, P = 0.04) or further restricting the subjects to those with a family history of asthma and those of European American ancestry (odds ratio = 3.16, P = 0.04). Shin et al. (2004) genotyped 550 Korean asthmatics and 171 Korean controls at 5 SNPs in TNFA and 2 SNPs in TNFB. Six common haplotypes could be constructed in the TNF gene cluster. The -308G-A polymorphism showed a significant association with the risk of asthma (p = 0.0004). The frequency of the -308A allele-containing genotype in asthmatics (9.8%) was much lower than that in normal controls (22.9%). The protective effects of this polymorphism on asthma were also evident in separated subgroups by atopic status (p = 0.05 in nonatopic subjects and p = 0.003 in atopic subjects). The most common haplotype of the TNF gene cluster (TNF-ht1-GGTCCGG) was associated with total serum IgE levels (147050) in asthma patients, especially in nonatopic patients (p = 0.004). Shin et al. (2004) concluded that genetic variants of TNF may be involved in the development of asthma and total serum IgE level in bronchial asthma patients. Aoki et al. (2006) did not find a significant association between the TNF -308G-A polymorphism and childhood atopic asthma in 2 independent Japanese populations; however, metaanalysis of a total of 2,477 asthma patients and 3,217 control individuals showed that the -308G-A polymorphism was significantly associated with asthma. The combined odds ratio was 1.46 for fixed or random effects (p = 0.0000001 and p = 0.00014, respectively). Quasney et al. (2001) stated that immunologic mechanisms resulting in macrophage infiltration and glial cell activation in the brain are thought to be involved in the pathophysiology of HIV dementia. Moreover, elevated levels of TNF-alpha have been found in the brains of patients with HIV dementia. In a study of 16 patients with HIV dementia, 45 HIV-infected patients without dementia, and 231 controls, they found an increased frequency of the -308A allele in patients with HIV dementia (0.28 vs 0.11 in controls and 0.07 in HIV patients without dementia). There were no individuals with the A/A genotype in either of the HIV-infected groups. Quasney et al. (2001) noted that the -308A allele is associated with higher TNF-alpha secretion in response to an inflammatory stimulus and that evidence has shown a role for TNF-alpha in neuronal damage, thus suggesting a genetic predisposition to the development of HIV dementia. Cox et al. (1994) reported that the -308A allele has an increased frequency in type I diabetes mellitus (222100). Krikovszky et al. (2002) studied ambulatory blood pressure in 126 Hungarian adolescents with type I diabetes mellitus. They found that the prevalence of the -308A allele was higher in diabetic adolescents than in the Hungarian reference population. TNFA genotype was associated with both systolic and diastolic blood pressure values. The -308A allele carrier state appeared to be associated with lower systolic and diastolic blood pressure values. Szalai et al. (2002) found an increased frequency of the C4B*Q0 allele (see 120820) in patients with severe coronary artery disease (CAD) who underwent bypass surgery compared to healthy controls (14.2% vs 9.9%). Investigation of specific allelic combinations revealed that C4B*Q0 in combination with the TNF-alpha -308A allele was significantly higher in CAD patients, particularly those with preoperative myocardial infarction. In a study of 147 patients with psoriatic arthritis (607507) and 389 controls, Balding et al. (2003) found that the -308A allele was significantly associated with both the presence and progression of joint erosions in psoriatic arthritis, and that the AA genotype was associated with the lowest mean age at onset of psoriasis (p = 0.0081). In a group of 261 patients with migraine without aura (see, e.g., 157300), Rainero et al. (2004) found that the G/G genotype was associated with an increased risk of migraine (odds ratio of 3.30). Rainero et al. (2004) suggested that TNF-alpha may be involved in the pathogenesis of migraine, perhaps due to its effect on cerebral blood flow; alternatively, a closely linked locus may be involved. In a metaanalysis of 19 studies, Lee et al. (2006) found an association between the -308A/A genotype and the -308A allele and systemic lupus erythematosus (SLE; 152700) in European-derived population (odds ratio of 4.0 for A/A and 2.1 for the A allele), but not in Asian-derived populations. (less)
|
|
risk factor
(Mar 01, 2006)
|
no assertion criteria provided
Method: literature only
|
MALARIA, CEREBRAL, SUSCEPTIBILITY TO
Affected status: not provided
Allele origin:
germline
|
OMIM
Accession: SCV000033442.2
First in ClinVar: Apr 04, 2013 Last updated: Sep 09, 2016 |
Comment on evidence:
Mira et al. (1999) referred to the TNFA promoter polymorphisms at position -308 as TNF1 for guanine and TNF2 for adenine. In a multicenter study … (more)
Mira et al. (1999) referred to the TNFA promoter polymorphisms at position -308 as TNF1 for guanine and TNF2 for adenine. In a multicenter study involving 7 institutions, they found a significant association between the TNF2 allele and susceptibility to septic shock and death from septic shock. The septic shock group was defined by the following 6 criteria within a 12-hour period: (1) clinical evidence of infection; (2) hyperthermia or hypothermia; (3) tachycardia; (4) tachypnea; (5) necessity for vasopressor to maintain systolic blood pressure; and (6) evidence of inadequate organ function or perfusion. Moraes et al. (2001) found that the TNF2 polymorphism is significantly associated with a stronger response (Mitsuda reaction) to lepromin in borderline tuberculoid leprosy patients. Epigenetic factors such as a history of BCG vaccination or a reversal reaction, but not both, were also associated with boosted Mitsuda reactions. Moraes et al. (2001) concluded that augmented TNF production may be associated with the TNF2 allele and an increased granulomatous response. Ma et al. (1998) found a higher frequency of the rare T2 TNFA polymorphism (-308G-A) in 43 Japanese Guillain-Barre syndrome (139393) patients who had had antecedent infection with C. jejuni than in 85 community controls. Witte et al. (2002) evaluated the relation between the -308G-A promoter polymorphism and risk of asthma (600807) in 236 cases and 275 nonasthmatic controls. Logistic regression analyses indicated that having 1 or 2 copies of the -308A allele increased the risk of asthma (odds ratio = 1.58), the magnitude of which was increased when restricting the cases to those with acute asthma (odds ratio = 1.86, P = 0.04) or further restricting the subjects to those with a family history of asthma and those of European American ancestry (odds ratio = 3.16, P = 0.04). Shin et al. (2004) genotyped 550 Korean asthmatics and 171 Korean controls at 5 SNPs in TNFA and 2 SNPs in TNFB. Six common haplotypes could be constructed in the TNF gene cluster. The -308G-A polymorphism showed a significant association with the risk of asthma (p = 0.0004). The frequency of the -308A allele-containing genotype in asthmatics (9.8%) was much lower than that in normal controls (22.9%). The protective effects of this polymorphism on asthma were also evident in separated subgroups by atopic status (p = 0.05 in nonatopic subjects and p = 0.003 in atopic subjects). The most common haplotype of the TNF gene cluster (TNF-ht1-GGTCCGG) was associated with total serum IgE levels (147050) in asthma patients, especially in nonatopic patients (p = 0.004). Shin et al. (2004) concluded that genetic variants of TNF may be involved in the development of asthma and total serum IgE level in bronchial asthma patients. Aoki et al. (2006) did not find a significant association between the TNF -308G-A polymorphism and childhood atopic asthma in 2 independent Japanese populations; however, metaanalysis of a total of 2,477 asthma patients and 3,217 control individuals showed that the -308G-A polymorphism was significantly associated with asthma. The combined odds ratio was 1.46 for fixed or random effects (p = 0.0000001 and p = 0.00014, respectively). Quasney et al. (2001) stated that immunologic mechanisms resulting in macrophage infiltration and glial cell activation in the brain are thought to be involved in the pathophysiology of HIV dementia. Moreover, elevated levels of TNF-alpha have been found in the brains of patients with HIV dementia. In a study of 16 patients with HIV dementia, 45 HIV-infected patients without dementia, and 231 controls, they found an increased frequency of the -308A allele in patients with HIV dementia (0.28 vs 0.11 in controls and 0.07 in HIV patients without dementia). There were no individuals with the A/A genotype in either of the HIV-infected groups. Quasney et al. (2001) noted that the -308A allele is associated with higher TNF-alpha secretion in response to an inflammatory stimulus and that evidence has shown a role for TNF-alpha in neuronal damage, thus suggesting a genetic predisposition to the development of HIV dementia. Cox et al. (1994) reported that the -308A allele has an increased frequency in type I diabetes mellitus (222100). Krikovszky et al. (2002) studied ambulatory blood pressure in 126 Hungarian adolescents with type I diabetes mellitus. They found that the prevalence of the -308A allele was higher in diabetic adolescents than in the Hungarian reference population. TNFA genotype was associated with both systolic and diastolic blood pressure values. The -308A allele carrier state appeared to be associated with lower systolic and diastolic blood pressure values. Szalai et al. (2002) found an increased frequency of the C4B*Q0 allele (see 120820) in patients with severe coronary artery disease (CAD) who underwent bypass surgery compared to healthy controls (14.2% vs 9.9%). Investigation of specific allelic combinations revealed that C4B*Q0 in combination with the TNF-alpha -308A allele was significantly higher in CAD patients, particularly those with preoperative myocardial infarction. In a study of 147 patients with psoriatic arthritis (607507) and 389 controls, Balding et al. (2003) found that the -308A allele was significantly associated with both the presence and progression of joint erosions in psoriatic arthritis, and that the AA genotype was associated with the lowest mean age at onset of psoriasis (p = 0.0081). In a group of 261 patients with migraine without aura (see, e.g., 157300), Rainero et al. (2004) found that the G/G genotype was associated with an increased risk of migraine (odds ratio of 3.30). Rainero et al. (2004) suggested that TNF-alpha may be involved in the pathogenesis of migraine, perhaps due to its effect on cerebral blood flow; alternatively, a closely linked locus may be involved. In a metaanalysis of 19 studies, Lee et al. (2006) found an association between the -308A/A genotype and the -308A allele and systemic lupus erythematosus (SLE; 152700) in European-derived population (odds ratio of 4.0 for A/A and 2.1 for the A allele), but not in Asian-derived populations. (less)
|
|
risk factor
(Mar 01, 2006)
|
no assertion criteria provided
Method: literature only
|
HUMAN IMMUNODEFICIENCY VIRUS DEMENTIA, SUSCEPTIBILITY TO
Affected status: not provided
Allele origin:
germline
|
OMIM
Accession: SCV000033438.2
First in ClinVar: Apr 04, 2013 Last updated: Sep 09, 2016 |
Comment on evidence:
Mira et al. (1999) referred to the TNFA promoter polymorphisms at position -308 as TNF1 for guanine and TNF2 for adenine. In a multicenter study … (more)
Mira et al. (1999) referred to the TNFA promoter polymorphisms at position -308 as TNF1 for guanine and TNF2 for adenine. In a multicenter study involving 7 institutions, they found a significant association between the TNF2 allele and susceptibility to septic shock and death from septic shock. The septic shock group was defined by the following 6 criteria within a 12-hour period: (1) clinical evidence of infection; (2) hyperthermia or hypothermia; (3) tachycardia; (4) tachypnea; (5) necessity for vasopressor to maintain systolic blood pressure; and (6) evidence of inadequate organ function or perfusion. Moraes et al. (2001) found that the TNF2 polymorphism is significantly associated with a stronger response (Mitsuda reaction) to lepromin in borderline tuberculoid leprosy patients. Epigenetic factors such as a history of BCG vaccination or a reversal reaction, but not both, were also associated with boosted Mitsuda reactions. Moraes et al. (2001) concluded that augmented TNF production may be associated with the TNF2 allele and an increased granulomatous response. Ma et al. (1998) found a higher frequency of the rare T2 TNFA polymorphism (-308G-A) in 43 Japanese Guillain-Barre syndrome (139393) patients who had had antecedent infection with C. jejuni than in 85 community controls. Witte et al. (2002) evaluated the relation between the -308G-A promoter polymorphism and risk of asthma (600807) in 236 cases and 275 nonasthmatic controls. Logistic regression analyses indicated that having 1 or 2 copies of the -308A allele increased the risk of asthma (odds ratio = 1.58), the magnitude of which was increased when restricting the cases to those with acute asthma (odds ratio = 1.86, P = 0.04) or further restricting the subjects to those with a family history of asthma and those of European American ancestry (odds ratio = 3.16, P = 0.04). Shin et al. (2004) genotyped 550 Korean asthmatics and 171 Korean controls at 5 SNPs in TNFA and 2 SNPs in TNFB. Six common haplotypes could be constructed in the TNF gene cluster. The -308G-A polymorphism showed a significant association with the risk of asthma (p = 0.0004). The frequency of the -308A allele-containing genotype in asthmatics (9.8%) was much lower than that in normal controls (22.9%). The protective effects of this polymorphism on asthma were also evident in separated subgroups by atopic status (p = 0.05 in nonatopic subjects and p = 0.003 in atopic subjects). The most common haplotype of the TNF gene cluster (TNF-ht1-GGTCCGG) was associated with total serum IgE levels (147050) in asthma patients, especially in nonatopic patients (p = 0.004). Shin et al. (2004) concluded that genetic variants of TNF may be involved in the development of asthma and total serum IgE level in bronchial asthma patients. Aoki et al. (2006) did not find a significant association between the TNF -308G-A polymorphism and childhood atopic asthma in 2 independent Japanese populations; however, metaanalysis of a total of 2,477 asthma patients and 3,217 control individuals showed that the -308G-A polymorphism was significantly associated with asthma. The combined odds ratio was 1.46 for fixed or random effects (p = 0.0000001 and p = 0.00014, respectively). Quasney et al. (2001) stated that immunologic mechanisms resulting in macrophage infiltration and glial cell activation in the brain are thought to be involved in the pathophysiology of HIV dementia. Moreover, elevated levels of TNF-alpha have been found in the brains of patients with HIV dementia. In a study of 16 patients with HIV dementia, 45 HIV-infected patients without dementia, and 231 controls, they found an increased frequency of the -308A allele in patients with HIV dementia (0.28 vs 0.11 in controls and 0.07 in HIV patients without dementia). There were no individuals with the A/A genotype in either of the HIV-infected groups. Quasney et al. (2001) noted that the -308A allele is associated with higher TNF-alpha secretion in response to an inflammatory stimulus and that evidence has shown a role for TNF-alpha in neuronal damage, thus suggesting a genetic predisposition to the development of HIV dementia. Cox et al. (1994) reported that the -308A allele has an increased frequency in type I diabetes mellitus (222100). Krikovszky et al. (2002) studied ambulatory blood pressure in 126 Hungarian adolescents with type I diabetes mellitus. They found that the prevalence of the -308A allele was higher in diabetic adolescents than in the Hungarian reference population. TNFA genotype was associated with both systolic and diastolic blood pressure values. The -308A allele carrier state appeared to be associated with lower systolic and diastolic blood pressure values. Szalai et al. (2002) found an increased frequency of the C4B*Q0 allele (see 120820) in patients with severe coronary artery disease (CAD) who underwent bypass surgery compared to healthy controls (14.2% vs 9.9%). Investigation of specific allelic combinations revealed that C4B*Q0 in combination with the TNF-alpha -308A allele was significantly higher in CAD patients, particularly those with preoperative myocardial infarction. In a study of 147 patients with psoriatic arthritis (607507) and 389 controls, Balding et al. (2003) found that the -308A allele was significantly associated with both the presence and progression of joint erosions in psoriatic arthritis, and that the AA genotype was associated with the lowest mean age at onset of psoriasis (p = 0.0081). In a group of 261 patients with migraine without aura (see, e.g., 157300), Rainero et al. (2004) found that the G/G genotype was associated with an increased risk of migraine (odds ratio of 3.30). Rainero et al. (2004) suggested that TNF-alpha may be involved in the pathogenesis of migraine, perhaps due to its effect on cerebral blood flow; alternatively, a closely linked locus may be involved. In a metaanalysis of 19 studies, Lee et al. (2006) found an association between the -308A/A genotype and the -308A allele and systemic lupus erythematosus (SLE; 152700) in European-derived population (odds ratio of 4.0 for A/A and 2.1 for the A allele), but not in Asian-derived populations. (less)
|
|
risk factor
(Mar 01, 2006)
|
no assertion criteria provided
Method: literature only
|
SEPTIC SHOCK, SUSCEPTIBILITY TO
Affected status: not provided
Allele origin:
germline
|
OMIM
Accession: SCV000033436.2
First in ClinVar: Apr 04, 2013 Last updated: Sep 09, 2016 |
Comment on evidence:
Mira et al. (1999) referred to the TNFA promoter polymorphisms at position -308 as TNF1 for guanine and TNF2 for adenine. In a multicenter study … (more)
Mira et al. (1999) referred to the TNFA promoter polymorphisms at position -308 as TNF1 for guanine and TNF2 for adenine. In a multicenter study involving 7 institutions, they found a significant association between the TNF2 allele and susceptibility to septic shock and death from septic shock. The septic shock group was defined by the following 6 criteria within a 12-hour period: (1) clinical evidence of infection; (2) hyperthermia or hypothermia; (3) tachycardia; (4) tachypnea; (5) necessity for vasopressor to maintain systolic blood pressure; and (6) evidence of inadequate organ function or perfusion. Moraes et al. (2001) found that the TNF2 polymorphism is significantly associated with a stronger response (Mitsuda reaction) to lepromin in borderline tuberculoid leprosy patients. Epigenetic factors such as a history of BCG vaccination or a reversal reaction, but not both, were also associated with boosted Mitsuda reactions. Moraes et al. (2001) concluded that augmented TNF production may be associated with the TNF2 allele and an increased granulomatous response. Ma et al. (1998) found a higher frequency of the rare T2 TNFA polymorphism (-308G-A) in 43 Japanese Guillain-Barre syndrome (139393) patients who had had antecedent infection with C. jejuni than in 85 community controls. Witte et al. (2002) evaluated the relation between the -308G-A promoter polymorphism and risk of asthma (600807) in 236 cases and 275 nonasthmatic controls. Logistic regression analyses indicated that having 1 or 2 copies of the -308A allele increased the risk of asthma (odds ratio = 1.58), the magnitude of which was increased when restricting the cases to those with acute asthma (odds ratio = 1.86, P = 0.04) or further restricting the subjects to those with a family history of asthma and those of European American ancestry (odds ratio = 3.16, P = 0.04). Shin et al. (2004) genotyped 550 Korean asthmatics and 171 Korean controls at 5 SNPs in TNFA and 2 SNPs in TNFB. Six common haplotypes could be constructed in the TNF gene cluster. The -308G-A polymorphism showed a significant association with the risk of asthma (p = 0.0004). The frequency of the -308A allele-containing genotype in asthmatics (9.8%) was much lower than that in normal controls (22.9%). The protective effects of this polymorphism on asthma were also evident in separated subgroups by atopic status (p = 0.05 in nonatopic subjects and p = 0.003 in atopic subjects). The most common haplotype of the TNF gene cluster (TNF-ht1-GGTCCGG) was associated with total serum IgE levels (147050) in asthma patients, especially in nonatopic patients (p = 0.004). Shin et al. (2004) concluded that genetic variants of TNF may be involved in the development of asthma and total serum IgE level in bronchial asthma patients. Aoki et al. (2006) did not find a significant association between the TNF -308G-A polymorphism and childhood atopic asthma in 2 independent Japanese populations; however, metaanalysis of a total of 2,477 asthma patients and 3,217 control individuals showed that the -308G-A polymorphism was significantly associated with asthma. The combined odds ratio was 1.46 for fixed or random effects (p = 0.0000001 and p = 0.00014, respectively). Quasney et al. (2001) stated that immunologic mechanisms resulting in macrophage infiltration and glial cell activation in the brain are thought to be involved in the pathophysiology of HIV dementia. Moreover, elevated levels of TNF-alpha have been found in the brains of patients with HIV dementia. In a study of 16 patients with HIV dementia, 45 HIV-infected patients without dementia, and 231 controls, they found an increased frequency of the -308A allele in patients with HIV dementia (0.28 vs 0.11 in controls and 0.07 in HIV patients without dementia). There were no individuals with the A/A genotype in either of the HIV-infected groups. Quasney et al. (2001) noted that the -308A allele is associated with higher TNF-alpha secretion in response to an inflammatory stimulus and that evidence has shown a role for TNF-alpha in neuronal damage, thus suggesting a genetic predisposition to the development of HIV dementia. Cox et al. (1994) reported that the -308A allele has an increased frequency in type I diabetes mellitus (222100). Krikovszky et al. (2002) studied ambulatory blood pressure in 126 Hungarian adolescents with type I diabetes mellitus. They found that the prevalence of the -308A allele was higher in diabetic adolescents than in the Hungarian reference population. TNFA genotype was associated with both systolic and diastolic blood pressure values. The -308A allele carrier state appeared to be associated with lower systolic and diastolic blood pressure values. Szalai et al. (2002) found an increased frequency of the C4B*Q0 allele (see 120820) in patients with severe coronary artery disease (CAD) who underwent bypass surgery compared to healthy controls (14.2% vs 9.9%). Investigation of specific allelic combinations revealed that C4B*Q0 in combination with the TNF-alpha -308A allele was significantly higher in CAD patients, particularly those with preoperative myocardial infarction. In a study of 147 patients with psoriatic arthritis (607507) and 389 controls, Balding et al. (2003) found that the -308A allele was significantly associated with both the presence and progression of joint erosions in psoriatic arthritis, and that the AA genotype was associated with the lowest mean age at onset of psoriasis (p = 0.0081). In a group of 261 patients with migraine without aura (see, e.g., 157300), Rainero et al. (2004) found that the G/G genotype was associated with an increased risk of migraine (odds ratio of 3.30). Rainero et al. (2004) suggested that TNF-alpha may be involved in the pathogenesis of migraine, perhaps due to its effect on cerebral blood flow; alternatively, a closely linked locus may be involved. In a metaanalysis of 19 studies, Lee et al. (2006) found an association between the -308A/A genotype and the -308A allele and systemic lupus erythematosus (SLE; 152700) in European-derived population (odds ratio of 4.0 for A/A and 2.1 for the A allele), but not in Asian-derived populations. (less)
|
|
risk factor
(Mar 01, 2006)
|
no assertion criteria provided
Method: literature only
|
ASTHMA, SUSCEPTIBILITY TO
Affected status: not provided
Allele origin:
germline
|
OMIM
Accession: SCV000033437.2
First in ClinVar: Apr 04, 2013 Last updated: Sep 09, 2016 |
Comment on evidence:
Mira et al. (1999) referred to the TNFA promoter polymorphisms at position -308 as TNF1 for guanine and TNF2 for adenine. In a multicenter study … (more)
Mira et al. (1999) referred to the TNFA promoter polymorphisms at position -308 as TNF1 for guanine and TNF2 for adenine. In a multicenter study involving 7 institutions, they found a significant association between the TNF2 allele and susceptibility to septic shock and death from septic shock. The septic shock group was defined by the following 6 criteria within a 12-hour period: (1) clinical evidence of infection; (2) hyperthermia or hypothermia; (3) tachycardia; (4) tachypnea; (5) necessity for vasopressor to maintain systolic blood pressure; and (6) evidence of inadequate organ function or perfusion. Moraes et al. (2001) found that the TNF2 polymorphism is significantly associated with a stronger response (Mitsuda reaction) to lepromin in borderline tuberculoid leprosy patients. Epigenetic factors such as a history of BCG vaccination or a reversal reaction, but not both, were also associated with boosted Mitsuda reactions. Moraes et al. (2001) concluded that augmented TNF production may be associated with the TNF2 allele and an increased granulomatous response. Ma et al. (1998) found a higher frequency of the rare T2 TNFA polymorphism (-308G-A) in 43 Japanese Guillain-Barre syndrome (139393) patients who had had antecedent infection with C. jejuni than in 85 community controls. Witte et al. (2002) evaluated the relation between the -308G-A promoter polymorphism and risk of asthma (600807) in 236 cases and 275 nonasthmatic controls. Logistic regression analyses indicated that having 1 or 2 copies of the -308A allele increased the risk of asthma (odds ratio = 1.58), the magnitude of which was increased when restricting the cases to those with acute asthma (odds ratio = 1.86, P = 0.04) or further restricting the subjects to those with a family history of asthma and those of European American ancestry (odds ratio = 3.16, P = 0.04). Shin et al. (2004) genotyped 550 Korean asthmatics and 171 Korean controls at 5 SNPs in TNFA and 2 SNPs in TNFB. Six common haplotypes could be constructed in the TNF gene cluster. The -308G-A polymorphism showed a significant association with the risk of asthma (p = 0.0004). The frequency of the -308A allele-containing genotype in asthmatics (9.8%) was much lower than that in normal controls (22.9%). The protective effects of this polymorphism on asthma were also evident in separated subgroups by atopic status (p = 0.05 in nonatopic subjects and p = 0.003 in atopic subjects). The most common haplotype of the TNF gene cluster (TNF-ht1-GGTCCGG) was associated with total serum IgE levels (147050) in asthma patients, especially in nonatopic patients (p = 0.004). Shin et al. (2004) concluded that genetic variants of TNF may be involved in the development of asthma and total serum IgE level in bronchial asthma patients. Aoki et al. (2006) did not find a significant association between the TNF -308G-A polymorphism and childhood atopic asthma in 2 independent Japanese populations; however, metaanalysis of a total of 2,477 asthma patients and 3,217 control individuals showed that the -308G-A polymorphism was significantly associated with asthma. The combined odds ratio was 1.46 for fixed or random effects (p = 0.0000001 and p = 0.00014, respectively). Quasney et al. (2001) stated that immunologic mechanisms resulting in macrophage infiltration and glial cell activation in the brain are thought to be involved in the pathophysiology of HIV dementia. Moreover, elevated levels of TNF-alpha have been found in the brains of patients with HIV dementia. In a study of 16 patients with HIV dementia, 45 HIV-infected patients without dementia, and 231 controls, they found an increased frequency of the -308A allele in patients with HIV dementia (0.28 vs 0.11 in controls and 0.07 in HIV patients without dementia). There were no individuals with the A/A genotype in either of the HIV-infected groups. Quasney et al. (2001) noted that the -308A allele is associated with higher TNF-alpha secretion in response to an inflammatory stimulus and that evidence has shown a role for TNF-alpha in neuronal damage, thus suggesting a genetic predisposition to the development of HIV dementia. Cox et al. (1994) reported that the -308A allele has an increased frequency in type I diabetes mellitus (222100). Krikovszky et al. (2002) studied ambulatory blood pressure in 126 Hungarian adolescents with type I diabetes mellitus. They found that the prevalence of the -308A allele was higher in diabetic adolescents than in the Hungarian reference population. TNFA genotype was associated with both systolic and diastolic blood pressure values. The -308A allele carrier state appeared to be associated with lower systolic and diastolic blood pressure values. Szalai et al. (2002) found an increased frequency of the C4B*Q0 allele (see 120820) in patients with severe coronary artery disease (CAD) who underwent bypass surgery compared to healthy controls (14.2% vs 9.9%). Investigation of specific allelic combinations revealed that C4B*Q0 in combination with the TNF-alpha -308A allele was significantly higher in CAD patients, particularly those with preoperative myocardial infarction. In a study of 147 patients with psoriatic arthritis (607507) and 389 controls, Balding et al. (2003) found that the -308A allele was significantly associated with both the presence and progression of joint erosions in psoriatic arthritis, and that the AA genotype was associated with the lowest mean age at onset of psoriasis (p = 0.0081). In a group of 261 patients with migraine without aura (see, e.g., 157300), Rainero et al. (2004) found that the G/G genotype was associated with an increased risk of migraine (odds ratio of 3.30). Rainero et al. (2004) suggested that TNF-alpha may be involved in the pathogenesis of migraine, perhaps due to its effect on cerebral blood flow; alternatively, a closely linked locus may be involved. In a metaanalysis of 19 studies, Lee et al. (2006) found an association between the -308A/A genotype and the -308A allele and systemic lupus erythematosus (SLE; 152700) in European-derived population (odds ratio of 4.0 for A/A and 2.1 for the A allele), but not in Asian-derived populations. (less)
|
|
Uncertain significance
(Feb 09, 2021)
|
no assertion criteria provided
Method: research
|
Susceptibility to severe coronavirus disease (COVID-19)
Affected status: yes
Allele origin:
germline
|
HLA Laboratory, Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas
Accession: SCV001548220.1
First in ClinVar: Apr 13, 2021 Last updated: Apr 13, 2021 |
|
|
Uncertain significance
(Aug 07, 2021)
|
no assertion criteria provided
Method: research
|
Susceptibility to severe coronavirus disease (COVID-19) due to high plasma levels of TNF, TNFR, and/or TNFR4
Affected status: yes
Allele origin:
germline
|
HLA Laboratory, Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas
Accession: SCV001792246.1
First in ClinVar: Feb 20, 2022 Last updated: Feb 20, 2022 |
Comment:
Differences in plasma levels of TNFR2 according to genotypes
|
|
Affects
(Oct 20, 2021)
|
no assertion criteria provided
Method: case-control
|
Endometriosis
Affected status: yes
Allele origin:
somatic
|
Laboratorio de Investigación del Departamento de Salud, Universidad Iberoamericana A.C.
Accession: SCV002073726.1
First in ClinVar: Feb 13, 2022 Last updated: Feb 13, 2022 |
Comment:
Mexican mestizo women with severe stage of endometriosis have higher frequencies of TNF*2-, IL1B*2- and IL1RN*2-alleles, which may explain a possible correlation with disease severity … (more)
Mexican mestizo women with severe stage of endometriosis have higher frequencies of TNF*2-, IL1B*2- and IL1RN*2-alleles, which may explain a possible correlation with disease severity rather than predisposition or risk. (less)
Sex: female
Ethnicity/Population group: Mexican mestizo
Geographic origin: Mexico
|
|
click to load more click to collapse |
Germline Functional Evidence
There is no functional evidence in ClinVar for this variation. If you have generated functional data for this variation, please consider submitting that data to ClinVar. |
Citations for germline classification of this variant
HelpTitle | Author | Journal | Year | Link |
---|---|---|---|---|
Association between tumor necrosis factor-α (TNF-α) promoter -308 G/A and response to TNF-α blockers in rheumatoid arthritis: a meta-analysis. | Zeng Z | Modern rheumatology | 2013 | PMID: 22760475 |
TNF-alpha-308 G/A polymorphism and responsiveness to TNF-alpha blockade therapy in moderate to severe rheumatoid arthritis: a systematic review and meta-analysis. | O'Rielly DD | The pharmacogenomics journal | 2009 | PMID: 19365401 |
Association of the tumour necrosis factor-308 variant with differential response to anti-TNF agents in the treatment of rheumatoid arthritis. | Maxwell JR | Human molecular genetics | 2008 | PMID: 18713756 |
Influence of -308 A/G polymorphism in the tumor necrosis factor alpha gene on etanercept treatment in rheumatoid arthritis. | Guis S | Arthritis and rheumatism | 2007 | PMID: 18050183 |
The -308 tumour necrosis factor-alpha gene polymorphism predicts therapeutic response to TNFalpha-blockers in rheumatoid arthritis and spondyloarthritis patients. | Seitz M | Rheumatology (Oxford, England) | 2007 | PMID: 16720636 |
Association of TNF-alpha -308 G/A polymorphism with responsiveness to TNF-alpha-blockers in rheumatoid arthritis: a meta-analysis. | Lee YH | Rheumatology international | 2006 | PMID: 16909270 |
An association between asthma and TNF-308G/A polymorphism: meta-analysis. | Aoki T | Journal of human genetics | 2006 | PMID: 16865291 |
Meta-analysis of TNF-alpha promoter -308 A/G polymorphism and SLE susceptibility. | Lee YH | European journal of human genetics : EJHG | 2006 | PMID: 16418737 |
Association between the tumor necrosis factor-alpha -308 G/A gene polymorphism and migraine. | Rainero I | Neurology | 2004 | PMID: 14718719 |
Association of tumor necrosis factor polymorphisms with asthma and serum total IgE. | Shin HD | Human molecular genetics | 2004 | PMID: 14681301 |
Genetic markers for the efficacy of tumour necrosis factor blocking therapy in rheumatoid arthritis. | Padyukov L | Annals of the rheumatic diseases | 2003 | PMID: 12759288 |
Cytokine gene polymorphisms: association with psoriatic arthritis susceptibility and severity. | Balding J | Arthritis and rheumatism | 2003 | PMID: 12746914 |
Association between G-308A polymorphism of the tumor necrosis factor-alpha gene and 24-hour ambulatory blood pressure values in type 1 diabetic adolescents. | Krikovszky D | Clinical genetics | 2002 | PMID: 12485196 |
Relation between tumour necrosis factor polymorphism TNFalpha-308 and risk of asthma. | Witte JS | European journal of human genetics : EJHG | 2002 | PMID: 11896460 |
Association of polymorphisms and allelic combinations in the tumour necrosis factor-alpha-complement MHC region with coronary artery disease. | Szalai C | Journal of medical genetics | 2002 | PMID: 11826025 |
Increased frequency of the tumor necrosis factor-alpha-308 A allele in adults with human immunodeficiency virus dementia. | Quasney MW | Annals of neurology | 2001 | PMID: 11506397 |
Tumor necrosis factor-alpha promoter polymorphism TNF2 is associated with a stronger delayed-type hypersensitivity reaction in the skin of borderline tuberculoid leprosy patients. | Moraes MO | Immunogenetics | 2001 | PMID: 11261930 |
Association of TNF2, a TNF-alpha promoter polymorphism, with septic shock susceptibility and mortality: a multicenter study. | Mira JP | JAMA | 1999 | PMID: 10450718 |
Genetic contribution of the tumor necrosis factor region in Guillain-Barré syndrome. | Ma JJ | Annals of neurology | 1998 | PMID: 9818939 |
Comparative analysis of the genetic associations of HLA-DR3 and tumour necrosis factor alpha with human IDDM. | Cox A | Diabetologia | 1994 | PMID: 8056188 |
https://www.pharmgkb.org/clinicalAnnotation/655384799 | - | - | - | - |
https://www.pharmgkb.org/variant/PA166156997 | - | - | - | - |
click to load more click to collapse |
Text-mined citations for rs1800629 ...
HelpRecord last updated Nov 10, 2024
This date represents the last time this VCV record was updated. The update may be due to an update to one of the included submitted records (SCVs), or due to an update that ClinVar made to the variant such as adding HGVS expressions or a rs number. So this date may be different from the date of the “most recent submission” reported at the top of this page.